Nanocarriers for delivery of platinum anticancer drugs by Oberoi, Hardeep S. et al.
Nanocarriers for delivery of platinum anticancer drugs☆
Hardeep S. Oberoia,1, Natalia V. Nukolovab,c,1, Alexander V. Kabanovb,d,*, and Tatiana K.
Bronicha,**
Alexander V. Kabanov: kabanov@email.unc.edu; Tatiana K. Bronich: tbronich@unmc.edu
aDepartment of Pharmaceutical Sciences and Center for Drug Delivery and Nanomedicine,
College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA
bDepartment of Chemistry, M.V. Lomonosov Moscow State University, Leninskie Gory, Moscow
119992, Russia
cRussian State Medical University, Department of Medical Nanobiotechnology, Ostrovityanova 1,
Moscow 117997, Russia
dCenter for Nanotechnology in Drug Delivery and Division of Molecular Therapeutics, UNC
Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA
Abstract
Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in
widespread clinical use especially for management of tumors of the ovary, testes, and the head and
neck. However, several dose limiting toxicities associated with platinum drug use, partial anti-
tumor response in most patients, development of drug resistance, tumor relapse, and many other
challenges have severely limited the patient quality of life. These limitations have motivated an
extensive research effort towards development of new strategies for improving platinum therapy.
Nanocarrier-based delivery of platinum compounds is one such area of intense research effort
beginning to provide encouraging preclinical and clinical results and may allow the development
of the next generation of platinum chemotherapy. This review highlights current understanding on
the pharmacology and limitations of platinum compounds in clinical use, and provides a
comprehensive analysis of various platinum–polymer complexes, micelles, dendrimers, liposomes
and other nanoparticles currently under investigation for delivery of platinum drugs.
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It has been 48 years since Rosenberg and colleagues while studying the effect of electric
field on bacteria made a serendipitous discovery that the products of hydrolysis of the
platinum electrode can inhibit bacterial growth [1]. Of these products the most potent was
cisplatin first described by Michele Peyrone in 1845, and known for a long time as
Peyrone’s salt. They also discovered that this compound can inhibit growth of cancer cells in
mouse models of sarcoma and leukemia [2]. These seminal studies were followed by Higby
and colleagues who carried out the clinical trial of cisplatin and reported response to the
drug in testicular and other tumors [3]. Cisplatin and other platinate derivatives are now
common in medical oncology, having a major impact in management of tumors of the
ovary, testes, head and neck and other cancers [4,5].
However, the dose limiting toxicities associated with platinum therapy has presented a
serious concern in clinic [6,7]. After decades of research the quest for new less toxic
platinum compounds and treatment regimens or delivery methods, which would eliminate
the associated toxicities and improve the anticancer efficacy, still goes on [8,9]. Carrier-
based delivery of anticancer platinates to the tumor sites is one such area of intense research.
It encompasses the use of polymeric conjugates and various other inclusions of platinates in
liposomes, micelles, dendrimers, inorganic or other solid particles, and other carriers [10–
12]. It is envisioned that such carriers may permit improved solubility of platinates, prolong
their half-life in the body, increase distribution of them into tumor sites, enable sustained
and/or triggered release of drugs in the tumors, decrease off-target distribution and effect of
platinates, reduce side effects of platinum agents as well as suppress development of drug
resistance [13,14]. Furthermore, carriers are now explored for simultaneous incorporation
and delivery of platinum drugs with other anticancer drugs for combination therapy [15,16].
The following sections convey the current understanding of the pharmacology, mechanism
of action and limitations of platinum compounds in clinical use, and analyze various
polymeric carriers for anticancer platinates.
2. Platinum anticancer drugs in oncology
An overview of approved platinum complexes is presented in Table 1. The platinum
complexes in worldwide clinical use, also termed classical platinum complexes, are
uncharged, cis-configured, square planar complexes with platinum in its +II oxidation state
(Pt(II)). The general formula to describe them is cis-[PtA2X2], where A2 represents two
monodentate or one bidentate ligands with nitrogen donor atoms and X2 represents two
monodentate or one bidentate anionic ligand(s). Table 1 represents a summary of the ligands
comprising clinically used platinum complexes. Based on studies pioneered by Cleare and
Hoeschele [17], several structure–activity relationships have been recognized. The
modification of the non-leaving group(s) A2 results in formation of structurally different
DNA adducts and thus alters the anticancer activity of the complexes. The modification of
the leaving group X2 affects the biodistribution of the complexes and thereby affects their
side effects.
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Cisplatin (cis-diamminedichloroplatinum(II)) was the first member of classical platinum
complexes. It entered the Phase I clinical trials in 1971 and by the end of 1970s became the
basis in combination chemotherapy for the treatment of advanced and metastatic testicular
germ-cell cancer [18]. Combinations of cisplatin and etoposide are the current regimens of
choice for this indication and have proven to be highly effective [19]. Although not curative,
the cisplatin therapy has substantially improved the average progression-free survival and
life span of patients in ovarian cancer [20]. Cisplatin is an essential component of
chemotherapy regimens for lung, head and neck, endometrial, bladder and oesophageal
cancers [21]. It is also accepted as alternative option in therapies of several other solid
tumors, including liver, gastric, brain, melanoma and soft-tissue sarcomas. Moreover, this
drug was shown to sensitize cancer cells to radiation and is widely used in combined
radiotherapy–chemotherapy treatments in patients with advanced squamous cell carcinoma
of the head and neck, lung and locally advanced cervical cancers [22–24].
The second-generation platinum drugs were developed to reduce the dose limiting toxicity
of cisplatin by slowing down the rate of aquation reactions with bidentate X2 ligands
(discussed in Section 4). This, carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato)
platinum(II)), was created by substituting the readily exchangeable chloride ligands with a
bidentate 1,1-cyclobutanedicarboxylic acid ligand [25]. Its reduced toxicity profile makes it
suitable for aggressive high-dose chemotherapy. This drug has been approved worldwide
and nearly replaced cisplatin in combination regimens with paclitaxel for treatment of
ovarian cancer [26]. This combination is also used in patients with non-small cell lung
cancer (NSCLC) [19], albeit in these patients the carboplatin–etoposide combination is often
preferred. At the same time carboplatin has limited effectiveness against testicular germ-cell
cancers, squamous cell carcinoma of the head and neck and bladder cancer. As a result,
cisplatin still remains the drug of choice for treatment of these cancers [19].
Nedaplatin or cis-diammineglycolatoplatinum(II), shows improved toxicological profile
compared to cisplatin and pharmacokinetic properties similar to carboplatin [27]. So far it
has limited regional approval in treatment of NSCLC, small cell lung cancer (SCLC),
oesophageal cancer and head and neck cancers [28]. In a small pilot study, response rate
against oesophageal cancers was shown to be good, and could further be improved with 5-
fluorouracil (5-FU) [29]. The patients with renal impairment are expected to benefit from
this regimen. In other clinical studies, nedaplatin activity in combination regimens, for
example, with vindesine for untreated NSCLC, was shown to be equivalent to that of
cisplatin [30]. However, nedaplatin still retains an advantage over cisplatin due to lower
toxicity.
The third generation platinum complexes were designed to overcome cellular resistance to
cisplatin and carboplatin. This design typically involves modification of the non-leaving A2
(ammine) ligands (Table 1). For example, cis-dichloro(1,2-diamminocyclohexane)
platinum(II) (DACHPt) is a potent anticancer agent with a broader spectrum of activity and
no cross-resistance compared to cisplatin [19]. It is however, poorly soluble, which was
addressed by further modification of the X2 ligand. Among the various derivatives studied,
oxaliplatin (1,2-diaminocyclohexane platinum(II) oxalate) having a relatively higher
solubility compared to DACHPt has gained worldwide approval [31]. This agent has proven
Oberoi et al. Page 3






















to be effective and increased efficacy of standard 5-FU/leucovorin therapy in advanced
colorectal cancer, whether its combination with 5-FU/leucovorin is now considered the first
line treatment [32]. Oxaliplatin has also great potential as a treatment option after failure of
cisplatin or carboplatin therapy. Clinical activity of oxaliplatin has been reported in both
relapsed or refractory ovarian cancer [33] and refractory germ-cell cancers [34]. Its activity
has also been shown in pretreated refractory or relapsed non-Hodgkin’s lymphoma,
anthracycline-resistant metastatic breast cancer and in NSCLC [35]. Additionally,
oxaliplatin has shown much less toxicity than cisplatin or carboplatin.
The other notable representatives of the third generation complexes include lobaplatin and
heptaplatin, which have found limited regional approval. Lobaplatin (1,2-diamino-
methylcyclobutane) platinum(II) lactate) is currently approved for chronic myelogenous
leukemia, metastatic breast cancer and SCLC [28]. Preclinical data suggested its favorable
toxicological profile and lack of cross-resistance to cisplatin [36]. However, the clinical data
regarding lack of cross-resistance is inconclusive. Heptaplatin (cis-malonatol [(4R, 5R)-4,5-
bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II)) is structurally similar to
lobaplatin, but has a bulkier ammine ligand. It is currently used in the treatment of gastric
cancer [37]. A recent Phase III study indicated that heptaplatin/5-FU regimen is comparable
to cisplatin/5-FU regimen, but has less severe hematological side effects [38]. No study of
this regimen in cisplatin resistant cancers has been reported so far.
Additionally a number of new platinum complexes, which have shown promising preclinical
and early phase clinical results, are now being evaluated in advanced stage clinical trials.
Some of these drug candidates are presented in Table 2. For example, picoplatin (ZD0473)
was designed specifically to overcome intrinsic or acquired resistance due to elevated
intracellular thiols [39]. Introducing the methyl group at the position 2 of the pyridine ring
of this complex results in steric hindrance and reduced reactivity towards sulfur donors such
as methionine and thiourea [39]. In Phase I and Phase II clinical trials, picoplatin
demonstrated activity in a variety of solid tumors, including lung (SCLC and NSCLC),
ovarian, colorectal and hormone-refractory prostate cancer [40]. However, in Phase III trials
picoplatin failed to show efficacy in advanced NSCLC and second line SCLC. It is still
being investigated in Phase II trials in metastatic colorectal cancer [41]. An interesting
feature of this complex is its ability to be administered orally. It is the first Pt(II) drug to
show good oral bioavailability and activity, and an oral formulation for clinical use is
awaited.
The new candidates in clinical trials also include ‘non-classical’ complexes, which are
structurally different from cisplatin such as the trans-geometry, trinuclear complex,
BBR3464, and the octahedral Pt(IV) complex, satraplatin. In preclinical studies comparing
BBR3464 to cisplatin the former derivative showed higher uptake [42,43], more rapid DNA
binding and higher number of long persisting inter-strand cross-links, which were less
inclined to repair [44]. Phase I studies of BBR3464 demonstrated its reduced toxicity
profile, much different from that of cisplatin [45]. Although positive results were observed
in Phase II studies with NSCLC [46], this drug candidate has not moved into Phase III. The
results for Phase II studies in locally advanced and metastatic pancreatic cancer have not
been reported yet.
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Of particular interest are octahedral Pt(IV) complexes, which tend to be less reactive and are
better suited for oral administration than their Pt(II) counterparts [47]. These compounds,
also called fourth generation complexes, are characterized by higher oxidation state of the
metal center + IV and presence of two axial leaving ligands. Their general formula is cis-
[PtA2X2Y2], where Y2 being two other axial monodentate anionic leaving groups. These
complexes are prodrugs, which are eventually transformed into Pt(II) complexes due to
reduction to Pt(IV) and loss of axial ligands. Of this group, satraplatin is currently under
clinical evaluation [48]. It is readily absorbed by the gastro-intestinal mucosa and once in
the blood is reduced to yield at least six different active Pt(II) complexes [48]. Phase I
studies indicated a toxicological profile similar to carboplatin and different from cisplatin
[49]. Phase II studies revealed activity in previously untreated patients with SCLC and
prostate cancer. A Phase III trial evaluated satraplatin with and without prednisone in
hormone-refractory prostate cancer and indicated a 40% reduction in risk of progression
compared to placebo [50]. Currently satraplatin is undergoing variety of Phase I, II and III
clinical trials in combination with various other drugs such as bevacizumab for prostate
cancer, abraxane for advanced cancers, and vinorelbine for advanced solid tumors.
3. Mechanisms of action of platinum drugs
There are three major factors defining the cytotoxicity of the platinum drugs: 1) cellular
accumulation of the drug; 2) intracellular aquation, sub-cellular distribution and binding to
the cellular targets; and 3) cellular recognition of platinum-induced damage leading the cell
to death (Fig. 1).
Cellular accumulation of the platinum drugs is directly related to their cytotoxicity. The
majority of cases with acquired cellular resistance to platinum drugs are associated with a
markedly reduced drug accumulation. The long held assumption that platinum is transported
into cells largely by passive diffusion has recently been challenged by studies involving the
role of various cellular transporters. In particular, the major copper influx transporter, copper
transporter 1 (CTR1), is now considered the principal gateway for the accumulation of
cisplatin and carboplatin in the tumor cells [51]. A positive correlation between decrease in
CTR1 expression and increase in acquired cisplatin resistance was shown among ovarian
cancer cell lines [52]. The CTR1 genetic knockout cells were shown to be resistant to
cisplatin in vivo [53]. In contrast to cisplatin and carboplatin, the accumulation of oxaliplatin
seems to be less dependent on CTR1 [51]. In addition, two copper efflux transporters,
ATP7A and ATP7B have also been shown to regulate platinum drug accumulation. A small
increase in ATP7A expression produced resistance to all three clinically available Pt drugs
(cisplatin, carboplatin and oxaliplatin); however, the exact mechanism behind this effect is
not clearly understood [54]. A more direct relationship between increased ATP7B
expression and cisplatin and carboplatin efflux was shown by Katano et al. [55]. Moreover,
in addition to copper transporters, organic cation transporters (OCTs) have also been
implicated in the facilitated transport of platinum drugs. The nature of the non-leaving group
coordinated to platinum, such as the DACH moiety in oxaliplatin, was shown to be a key for
selective uptake of these platinum complexes by OCTs [56]. Thus, it appears that platinum
drug accumulation is due to a combination of passive, active, and facilitated transport
mechanisms.
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Aquation is one of the key processes in the pharmacology of platinum drugs. In aqueous
media, the platinum complexes undergo stepwise aquation reactions, in which the chloride
ions are replaced by the water molecules resulting in the formation of cationic mono- and di-
aqua complexes (the most active forms), and to a lesser extent hydroxo-bridged platinum(II)
multimers (the least active forms) [57]. The rates of aquation of platinum complexes are
determined mainly by the concentration of the chloride ions in biological fluids. Thus, the
low concentration of chloride in the cells (4–12 mM) favors formation of the cationic aqua
forms of the platinum complexes. In contrast, the high concentration of chloride in the blood
(100 mM) favors existence of relatively stable neutral state of the platinum complexes [58].
The role of aquation in the pharmacology of platinum drugs is illustrated in Fig. 1 using
cisplatin as an example. This process is believed to play two major roles. First, the cationic
aqua derivatives of the platinum drugs do not readily diffuse out of the cell through the cell
membrane and are trapped within the cell. Second, the aquation chemically activates the
drug, which is essential for its binding to intracellular targets: proteins, RNA and, most
importantly, DNA [58]. Furthermore, the rate of exchange of the X2 ligands with water
affects the toxicity of the platinum complexes. Rapid aquation in the blood produces highly
active platinum species, which react with various molecules in the blood and cause severe
systemic toxicity. Slower aquation reduces toxicity, prolongs plasma half-life, but also
reduces the antitumor activity of the drug [59]. This concept is best exemplified by
carboplatin, the better tolerability of which has largely been attributed to its higher stability
and lower reactivity. The aquation rate of carboplatin in neutral chloride-free phosphate
buffer is approximately 100 times slower than that for cisplatin [60]. Similarly, platinum
compounds with bidentate X2 ligands such as oxaliplatin also have slower rates of aquation
and are therefore more stable in aqueous media and less toxic [61].
The ability to react with various cellular targets underlies the cytotoxicity of the platinum
drugs. Of these cellular targets the DNA is undoubtedly the most important in exhibiting the
anticancer effect [62]. Biochemical studies demonstrated that formation of Pt-DNA adducts
significantly changes the structure of the target DNA, causing the unwinding, bending and
destabilization of the DNA duplex [63]. The more common 1,2- or 1,3-intrastrand cross-
links unwind the DNA duplex in the proximity of the site of platination and bend it toward
the major groove [64]. In contrast, the less prevalent inter-strand cross-links bend the helix
toward the minor groove [64]. The correlations between the Pt-DNA adduct levels and the
cytotoxic responses of the cells to these drugs have been long known. Analysis of the DNA
from the patients treated with cisplatin demonstrated formation of intra-strand Pt-adducts
with approximately 65% of these adducts being 1,2-d(GpG), 25% 1,2-d(ApG), and 5–10%
1,3-d(GpNpG) [65]. Additionally, a small percentage of adducts display inter-strand cross-
links or mono-functional modifications.
Platinum drugs containing different leaving groups X2 may exhibit different kinetics of
DNA binding and produce different DNA-adduct profiles [66]. Thus, oxaliplatin generates a
disparate adduct profile compared to cisplatin [61]. The oxaliplatin adducts albeit being
significantly less frequent are yet more cytotoxic than those of cisplatin. The chemical
nature of the non-leaving group A2 can affect the structures of Pt-DNA adducts and cause
distinctive structural distortions of DNA, which, in turn, may alter the recognition of the
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platinum lesions by the repair machinery and contribute to the differences in cytotoxicity of
the platinum drugs [67].
The interaction between the Pt-DNA damaged site and nuclear proteins triggers the signal
transduction pathways (AKT, c-ABL, p53, MAPK and others) that will ultimately seal the
fate of the treated cells (Fig. 1). For example, the DNA-damage recognition proteins
selectively recognize severely distorted DNA generated by formation of Pt-DNA cross-links
(Table 3). Other proteins such as histones, DNA and RNA polymerases involved in DNA
packaging are coming in frequent contact with the DNA duplex and unavoidably encounter
Pt-DNA adducts (Table 3) [58]. There seems to be an individualized cellular response to
these events, which is due to the heterogeneity of these interactions, further complicated by
the differential expression of these proteins in different cell types, transcriptional,
translational and post-translational regulation of their cellular levels, and cross-talk between
the various downstream signaling molecules [58,68]. Numerous pathways are involved in
the signaling DNA damage, arresting the cell cycle, repairing platinated DNA (transcription-
coupled repair, global genomic repair) and triggering cell death through apoptosis or
necrosis [4]. The knowledge of these processes is still incomplete and much remains to be
elucidated.
Several additional mechanisms, other than DNA-platination, have also been implicated in
the cytotoxicity of platinum drugs. Thus, platinum complexes can react with a number of
non-DNA cellular components such as glutathione [69], which may play a part in
cytotoxicity and toxicity profile of platinum drugs. There is evidence that cisplatin binds to
tubulin, induces partial microtubule depolymerization and therefore leads to disruption of
the cytoskeleton in tumor cells [70]. Cisplatin has been also reported to bind at C-terminal
part of the molecular chaperone, Hsp90 and to interfere with its nucleotide binding [71].
Furthermore, cisplatin is prone to interact with phosphatidylserin and other phospholipid
components of the cellular membranes and thus modulate their function [72]. A recent study
reported that cisplatin induces redistribution of the death receptor CD95 into membrane lipid
rafts of human colon cancer cell lines, which contributes to their sensitization to CD95-
mediated apoptosis [73].
4. Limitations to platinum drug therapy
Majority of patients treated with platinum drugs, with the exception of the testicular cancer
patients, experience only partial response with numerous systemic toxicities preventing
administration of higher drug doses. Some of the toxicities to a varying degree are common
to most platinum drugs. Some others are unique to specific platinum drugs.
For instance, nephrotoxicity is the major dose limiting toxicity associated with cisplatin.
Irreversible renal failure requiring dialysis is observed with large doses (exceeding 100
mg/m2/course) or multiple courses of cisplatin treatment. Cisplatin nephrotoxicity is often
seen 10 days post administration and is manifested as permanent reduction in glomerular
filtration rate, higher serum creatinine, and reduced serum magnesium and potassium levels
[74–77]. These side effects are generally followed by histopathological changes,
characterized by prominent tubular cell death due to necrosis and apoptosis [78]. The drug
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induces injury and death of tubular cells [79] and stimulates robust inflammatory response,
further contributing to renal tissue damage [80]. Moreover it may also induce injury to renal
vasculature and result in decreased blood flow and ischemic injury to the kidneys [80].
These events, together, culminate in the loss of renal function during cisplatin
nephrotoxicity, triggering acute renal failure. Additionally, cisplatin induces chronic
nephrotoxicity characterized by altered nephron structure and continued nephron functional
impairment [77]. The incidence of renal toxicities with carboplatin is generally lower and
much less severe than that with cisplatin [81,82]. With continued carboplatin therapy some
patients can experience subclinical tubular damage that can develop into overt
nephrotoxicity [83]. The potential for renal failure in patients previously treated with
cisplatin may be increased requiring a reduction in carboplatin doses [84]. Oxaliplatin is
considered to be the least nephrotoxic amongst the platinum drugs in clinical use [85].
However, there have been several reported cases of renal failure with repeated cycles of
oxaliplatin administration [86–88].
Neurotoxicity is another common side effect of platinum chemotherapy. Cisplatin treatment
often results in the damage of the dorsal root ganglion [7]. The drug acts as a calcium
channel blocker, changing intracellular calcium homeostasis and leading to apoptosis of
exposed neurons of the dorsal root ganglion [89]. Predominant symptoms include numbness
and tingling, abnormal sensation, disturbances of position, and relative sparing of motor
units [90]. These adverse neurological effects, with peak severity around 1–4 months after
the end of weekly cisplatin regimen, are usually reversible but are long-lasting in many
cases [91]. With carboplatin where hematological toxicity is dose limiting the neurotoxicity
is not generally observed at the clinically relevant doses. Oxaliplatin treatment is associated
with two different forms of toxicity. First, after few infusions of this drug there is a transient
acute syndrome accompanied with muscular cramps and spasms, which typically resolve
within days of drug infusion [92]. Second, the drug causes gradual development of the dose
limiting cumulative sensory neuropathy, which is similar to cisplatin effect. The
characteristic symptoms include persisting abnormal sensation and paresthesias of the
extremities, impaired sensory ataxia and deficits in fine sensory motor coordination, which
may impair normal life [85].
Toxicity to sensory systems is more common with cisplatin than with carboplatin and
oxaliplatin [93]. In particular, cisplatin causes ototoxicity especially in patients less than 5
years old, with adolescents/ adults being the least affected [94]. The ototoxicity of the drug
is caused by the damage to the organ of Corti and manifested as high-frequency hearing loss
and tinnitus [95]. There have been few reports of ototoxicity with carboplatin however their
severity was much less than with cisplatin [96]. Moreover, high dose cisplatin therapy was
reported to induce visual impairments due to retinal damage [97]. In contrast, carboplatin
and oxaliplatin seldom induce visual disturbances [7].
Haematological side effects are more common with carboplatin compared to cisplatin and
oxaliplatin. Carboplatin exerts potent myelosuppression resulting in thrombocytopenia and
neutropenia [98]. High-dose carboplatin chemotherapy is generally associated with life
threatening hematological toxicity, requiring prophylactic use of recombinant hemopoietic
growth factors [99]. Cisplatin treatment causes anemia requiring the prophylactic use of
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erythropoietin or transfusion of erythrocytes [100]. Oxaliplatin generally induces mild
myelosuppression with only a small percentage of patients experiencing severe anemia
[101].
Emetogenicity is most severe with cisplatin treatment amongst the clinically used platinum
drugs [102]. A very high percentage of cisplatin-treated patients experience severe nausea
and vomiting. While these adverse effects are also common with oxaliplatin and carboplatin
treatment the symptoms are generally mild to moderate compared to those with cisplatin
treatment [66,101].
Immunological side effects including hypersensitivity reactions associated with respiratory
dysfunction, gastrointestinal discomfort and rashes, have been common for platinate drugs
[103–105]. Cisplatin may also cause anaphylactic shock, asthma or hives [106]. These
adverse effects are somewhat less frequent with carboplatin and oxaliplatin treatment but
can be equally severe [107], necessitating either withdrawal from the drug use or
premedication with steroids and antihistamines [108,109]. Interestingly, patients were
reported to be cross-reactive to several platinum drugs [103].
There is some evidence indicating that platinum drugs are mutagenic. Particularly, the risk
of developing secondary leukemia while receiving platinum based chemotherapy can
increase by 4-fold [110]. Additionally, platinum compounds can cross the placenta and
cause fetal damage.
Some of the adverse events have become manageable by concomitant clinical strategies.
These include pre-hydration and forced diuresis, which reduces nephrotoxicity [111],
continuous administration of anti-emetics such as serotonin antagonists, which reduce
nausea/vomiting [112], co-administration of amifostine, which somewhat reduces the
nephro- and neurotoxicity [113], and various other chemoprotectant approaches. However,
these additional procedures have limited benefit, require complex dosage regimens to
minimize drug–drug interactions, and at times have irreversible side effects of their own.
Another major problem associated with platinum therapy is the development of drug
resistance. For example, 95% of patients with SCLC relapse after initial treatment because
of acquired drug resistance, resulting in extremely low 5-year survival rates [114]. Studies
have linked the development of platinum drug resistance to altered drug transport [115],
glutathione system [116], DNA repair and apoptotic genes [117]. Approaches to overcome
platinum drug resistance have also been widely investigated. Some of these approaches have
shown limited success. In particular, intraperitoneal administration of cisplatin appears to be
superior over intravenous administration in selected patients with ovarian cancer [118].
However, new drugs and modalities to overcome or prevent platinum drug resistance remain
an unmet need for majority of malignancies.
Altogether, albeit platinum therapy enabled major advancements in oncology it is often
hindered by adverse side effects of platinum drugs, and development of drug resistance.
Additional hurdles include low bioavailability of platinum drugs and their low water
solubility (which necessitates prolonged infusions of the drug in the patient). These hurdles
severely limit the patient’s quality of life. In an extensive effort to overcome these
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limitations many new platinum and other metal complexes were discovered and testing of as
anticancer agents [119]. Nevertheless only few of these agents reached an advanced stage of
clinical development (Table 2) and even less made it to the clinic (Table 1). Only three
platinum drugs—cisplatin, carboplatin and oxaliplatin, have received a worldwide clinical
approval. With the inventory of failed platinum complexes becoming ever more voluminous
(Table 4), the prospect of finding active platinum complexes with a simple set of ligands and
better therapeutic properties in comparison to cisplatin, carboplatin and oxaliplatin appears
bleak. This has necessitated exploration of alternate strategies such as the use of targeted
platinum complexes or carrier-based delivery approaches.
5. Platinum drug delivery using nanocarriers
Carrier-based delivery of anticancer drugs has received much attention in recent years
because of its potential for improving drug efficacy, reducing unwanted side effects and
circumventing cellular accumulation mediated drug resistance (Fig. 2). Such delivery
approaches often exploit differences between normal tissues and tumors to increase the
selectivity of the drug towards its intended target. Specifically, the enhanced permeability
and retention effect (EPR effect) is based on the increased permeability of macromolecules
in the tumor containing tissues coupled with poor lymphatic clearance and slow venous
return in these tissues [120,121]. While most clinically used anticancer drugs have low
molecular weight and rapidly pass through the membranes of both normal and cancerous
tissues, the drugs coupled to liposomes, lipid particles, micelles and various other polymeric
carriers selectively accumulate in tumors [122]. The nanoscale size of these carriers is
important, since it prevents their extravasation in normal tissues and removal by renal
clearance. As a result, long circulating polymeric carriers have greater exposure to the tumor
sites compared to low molecular drugs, which are rapidly cleared from circulation. Thus
EPR results in passive targeting of polymeric drugs to the tumors. This in some cases can be
further enhanced by active targeting using ligands or antibodies attached to the polymeric
drug that can selectively bind to tumor-specific moieties displayed at the target cells. Such
moieties are generally transporters, antigens or receptors with increased quantity or
functionality in tumors compared to normal tissues [123,124]. As further discussed below,
the delivery of the platinum complexes using polymeric carriers has largely focused on
passive targeting with relatively fewer examples of active targeting available (Table 5).
Generally, the drug is incorporated into polymeric carriers via encapsulation, covalent
attachment (conjugation), or complexation/ coordination binding. Most of the platinum
complexes are loaded into the carriers using encapsulation methods. Methods involving
conjugation and coordination binding have mostly involved cisplatin or DACHPt derivatives
due to the presence of replaceable X2 ligands in these complexes, which are not required for
drug activity. A few studies employed conjugation of drug to polymers containing amino
groups, which replaced the A2 ligands in the complexes.
A frequently occurring motif in the drug delivery systems is a hydrophilic polymer
polyethylene glycol (PEG), also known as polyethylene oxide (PEO) or polyoxyethylene
(POE). This polymer is inexpensive, has good biocompatibility and has been approved for
internal applications in humans by regulatory agencies [124]. PEG chains of molecular
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weights ranging from 1 to 15kDa have been widely employed as steric protectors in various
nano-particulate systems [125]. Owing to its high aqueous solubility, high mobility and
large exclusion volume, hydrated PEG forms a dense brush of polymer chains stretching out
and covering the particle surface [126]. This minimizes the interfacial free energy of the
particle surface and obstructs its interaction with other particles, proteins and other
biomolecules in blood, and cells. PEG coating hence serves to reduce particle opsonization
and is intended to make the carrier less recognizable by the reticuloendothelial system (RES)
in the liver and the spleen [125,127]. Although a complete ‘stealth’ effect has rarely been
demonstrated, prolonged blood circulation of the PEG coated carrier has widely been
observed and is considered crucial to its passive accumulation into tumors. Beside surface
characteristics, the size and shape of the nanocarriers also play roles in avoidance of various
clearance mechanisms and contribute into EPR-mediated tumor accumulation. Although
there is no ultimate answer on what is the size limit for tumor extravasation, it is generally
considered that particles with diameters <200 nm are more effective [128]. It is expected
that the particle characteristics favorable for the desired pharmacokinetic profile and
therapeutic index need to be tailored for each particular nanocarrier.
5.1. Clinical stage liposomal formulations for platinum complexes
Liposomes are lipid bilayer vesicles with an aqueous interior, usually prepared from a
variety of amphiphilic phospholipids (Fig. 3). Since their discovery by Bangham and
colleagues [129], liposomes became the pharmaceutical carriers of choice for numerous
practical applications. Several liposomal drug formulations have been approved, and many
more are under clinical evaluation [130]. One major advantage of this technology is its
ability to work with both hydrophobic and hydrophilic drugs; hydrophobic drugs can be
enclosed within the phospholipid bilayers, while hydrophilic drugs can be entrapped in the
aqueous cavity [131]. The physicochemical characteristics of liposomes (size, charge and
surface properties) are manageable. Thus, the size of the carrier could be adjusted by the
choice of an extrusion membrane of defined pore size, and the surface properties by
appropriate composition of phospholipids [131]. To avoid the recognition by RES system
and increase blood-circulation time, stealth liposomes with PEG molecules attached to their
surface were developed. Moreover, by modification of the terminal PEG molecule, such
liposomes can be conjugated with different targeting moieties (Fig. 3). Since the literature
related to liposomal delivery of platinum complexes is extensive, the following discussion is
limited to formulations, which currently are or had been in past under clinical evaluation
(Table 5).
Lipoplatin (Regulon, Inc.) is one of the most promising liposomal platinum drug
formulations under clinical investigation [132]. This formulation is prepared using soy
phosphatidylcholine (SPC-3), cholesterol, dipalmitoyl phosphatidylglycerol (DPPG) and
methoxy-PEG-distearoyl phosphatidylethanolamine (mPEG2000-DSPE). Lipoplatin
comprises ~9% cisplatin and ~91% lipids (w/w) corresponding to a drug-to-lipid ratio of
1:10 [133]. Its particle size is about 110 nm. Pre-clinical studies of Lipoplatin in mice, rats
and in severe combined immunodeficient mice reported that it has lower side effects, and
notably less nephrotoxicity compared to cisplatin [134]. Studies in dogs demonstrated that
Lipoplatin can be administered without the need for concurrent hydration protocols [135].
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Same liposomal carriers (with a reporter gene incorporated) were shown to extravasate
through defects of the leaky tumor vasculature and concentrate in solid tumors [136].
Phase I human studies of Lipoplatin albeit revealed its mild hematological and
gastrointestinal toxicity, did not show most other side effects characteristic of cisplatin
treatment such as nephro-, neuro- and ototoxicity, as well as hair loss [137]. Prolonged
blood circulation of Lipoplatin with a half-life of 3–5 days depending on the dose was also
observed, which was attributed to inclusion of PEGylated phospholipids [137]. In addition,
elevated accumulation of platinum in tumor tissues (10–50 times) in comparison with
adjacent normal tissues were detected [138].
Phase II studies of Lipoplatin in combination with gemcitabine also demonstrated significant
clinical benefit of the combination regimen in a number of patients previously resistant to
first- or second-line chemotherapy [139]. Lipoplatin has received orphan drug status by the
European Medicines Agency (EMA) for treatment of pancreatic adenocarcinoma [140]. Its
efficacy has been subsequently demonstrated in various Phase II/III studies, such as NSCLC
[141], HER2/neu negative metastatic breast cancer [142] and advanced gastric cancer [143].
In other human studies using Lipoplatin platinum accumulation in tumors and metastases
was shown to be higher than that in adjacent normal tissue 20 h after i.v. administration
[138]. Increased entry of Lipoplatin into cells could be due to its high levels of accumulation
in tumors as well as fusion of liposomes with the tumor cell membrane mediated by the
fusogenic anionic lipid DPPG [138,140].
SPI-77 (Alza Pharmaceuticals formerly Sequus Pharmaceuticals) is another liposomal
cisplatin, recently underwent clinical investigation. The formulation encapsulates cisplatin in
stealth liposomes composed of hydrogenated soy phosphatidylcholine, cholesterol and PEG-
modified phosphatidylethanolamine [144]. SPI-77 is prepared by adding the lipids dissolved
in ethanol to an aqueous solution of cisplatin and subsequent size extrusion of the resulting
dispersion through a 100nm pore size filter [145]. The drug loading is much lower (drug to
lipid ratio ~1:70) compared to Lipoplatin. Preclinical studies in tumor-bearing mice
indicated superior antitumor activity compared to cisplatin with higher cumulative doses of
SPI-77 being well tolerated [145]. SPI-77-treated animals had a 28-fold higher tumor
exposure to platinum with a 4-fold lower platinum exposure to kidneys relative to cisplatin-
treated animals [145].
Phase I studies of SPI-77 were conducted in both adult and pediatric patients with advanced
cancer not amenable to other cancer treatments. Despite about 100-fold higher plasma
platinum levels than those reported following comparable doses of cisplatin, SPI-77 was
well tolerated in all patients with lack of toxicities typical of conventional cisplatin regimen
[146]. Haematological toxicities were also reported to be mild; majority of patients did not
require antiemetics, lacked clinically significant peripheral neuropathy, and required no
additional hydration or forced diuresis [146]. Similar safety results were obtained in Phase II
trials in patients with advanced NSCLC, however the antitumor response was modest, which
resulted in early closure of the trial [147]. This could be due to the high stability of
liposomes and inefficient release of the drug from the carrier, as evidenced by very low
concentrations of free cisplatin observed in plasma as well as significantly reduced tumor
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DNA-platination [148]. Two other Phase I trials, one in combination with vinorelbine [149]
and another in combination with radiation [150], has also produced modest results. Recent
trials in advanced NSCLC [151] and in platinum-sensitive recurring ovarian cancer [152]
again indicated moderate antitumor response. This drug did not progress to Phase III
because of a lack of activity in Phase II trials. Nevertheless, all these trials demonstrated
much higher safety margin with the liposomal-cisplatin and lack of toxicities typical of the
free drug. These studies hence reflect the challenge of not only having to deliver platinum to
the tumor in a relatively inactive form, but also the subsequent need to achieve good release
and activation.
Liposomal formulations of oxaliplatin analogues have also been developed. Aroplatin (L-
NDDP, originally Aronex Pharmaceuticals now Agenus, Inc.) is a liposomal formulation of
cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (NDDP), a structural
analogue of oxaliplatin with two branched aliphatic leaving groups of ten carbon atoms,
incorporated in a matrix of dimyristoylphosphatidylcholine and dimyristoyl
phosphatidylglycerol (DMPG) (Table 5). Due to the lipophilic character of NDDP imparted
by the aliphatic side chains of this drug efficiently incorporates in the lipid compartment of
the liposomes (drug to lipid ratio ~1:15) [153]. Interestingly, NDDP is a liposome-
dependent drug where the liposomal carrier plays a crucial role in mediating the cytotoxicity
and antitumor activity of the drug, while the free drug itself has a very low cytotoxicity
[154]. Suggested mechanism of biological activity of NDDP includes the formation of active
intermediates in situ within the lipid bilayers, where the activation reaction was reported to
be highly dependent on the presence of DMPG and the lipophilic leaving group of NDDP
[155]. Preclinical studies in mice has shown L-NDDP activity against L1210 leukemia
resistant to cisplatin, B16 melanoma and murine M5076 reticulosarcoma exhibited without
any significant nephrotoxicity [156]. Studies in dogs also indicated better tolerability of L-
NDDP, accompanied with minimal renal dysfunction, and no cumulative myelosuppression
or liver dysfunction [157].
Subsequently, several Phase I trials of L-NDDP were conducted in patients with tumors
localized to a body cavity such as in malignant pleural mesothelioma [158], ovarian cancer
[159] and peritoneal carcinomatosis and sarcomatosis [160]. The drug was well tolerated in
patients with high peritoneal exposure compared to the plasma compartment [161]. A Phase
II trial of L-NDDP in mesothelioma patient population however revealed significant but
manageable toxicity. Although pathologic responses were highly encouraging, areas of
mesothelioma not in direct communication with the pleural space evaded drug exposure,
resulting in limited efficacy in some patients [162]. In patients with advanced colorectal
cancer that was refractory to 5-FU/leucovorin, capecitabine or irinotecan, a Phase II study
reported good tolerability and modest tumor response with single-agent oxaliplatin [163].
Lipoxal (Regulon, Inc.) is a liposomal oxaliplatin formulation produced using similar
technology as Lipoplatin. In vitro studies reported reduced cytotoxicity of Lipoxal against
tumor cells [164] however in vivo experiments reported equivalent efficacy with lower
toxicity compared to the free drug [165]. In Phase I study with advanced gastrointestinal
cancer patients, Lipoxal was well-tolerated and exhibited greatly reduced side effects
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compared to oxaliplatin, especially lower myelotoxicity and gastrointestinal tract toxicities
[165]. There is however no reports of any ongoing Phase II study.
MBP-426 (Mebiopharm Co., Ltd) is a transferrin (Tf)-conjugated N-glutaryl
phosphatidylethanolamine liposomal formulation of oxaliplatin, which can provide
preferential tumor targeting by binding to transferrin receptors [166]. Direct drug binding to
Tf receptor (TfR) and enhanced drug delivery mediated via uptake of MBP-426 by TfR was
demonstrated in human cancer cells in vitro [166]. MBP-426 also demonstrated potent
anticancer preclinical activity and has entered clinical trials. Results from Phase I clinical
trials for solid tumors were recently reported [167,168] and Phase II studies are ongoing.
5.2. Lipid coated nanocapsules for platinum complexes
Burger et al. in 2002 reported a method for preparation of cisplatin nanocapsules containing
platinum complexes with high encapsulation efficiency [169]. These nanocapsules are close
relatives of the liposomal formulations described above but are characterized by much
higher drug loading capacity (Fig. 2). According to this method nanoscale sized precipitates
of cisplatin covered with lipid bilayer were obtained by repeated freeze thaw cycles of a
concentrated aqueous solution of cisplatin mixed with negatively charged phospholipids (ζ-
potential about −40 mV). The resulting nanocapsules were bean shaped, with a
heterogeneous size distribution ranging from 50 to 250 nm, and a negative-potential [170].
Interestingly, analysis of the contents of the nanocapsules revealed a core composed of over
80% cisplatin covered with a lipid bilayer [170]. The average drug-to-lipid ratio in the
nanocapsules exceeded than 10:1. This formulation was further improved by including
cholesterol and PEG-modified lipids that increased stability of the lipid coat [171]. The
cytotoxicity of the cisplatin nanocapsules was more than two-fold greater than that of the
free drug. These nanocapsules were taken up in cells by caveolae-mediated endocytosis or
clathrin-mediated in cells lacking caveolin-1 expression [172].
The cisplatin nanocapsules displayed rapid accumulation in the liver, and more gradual
accumulation in the lung and the spleen, unexpectedly, similar plasma and tumor platinum
concentrations compare to the free drug. This formulation of cisplatin did not show
enhanced antitumor efficacy in an animal model of ovarian cancer [173]. The authors
attributed this to insufficient accumulation at of the nanocapsules the tumor site, rapid
adsorption of plasma proteins on the nanocapsules leading to disruption of capsule structure,
and probably the wrong choice of tumor model [174]. It was also suggested that the high
encapsulation efficiency could actually play and adverse role in drug delivery to the tumor.
At the administered dose nanocapsules has much lower amount of particles compared to
similar liposomal formulations, which could be insufficient to saturate the RES, leading to
preferential delivery of the nanocapsules to the liver and spleen, and hence inadequate
amounts available at the tumor [174].
Nonetheless, such nanocapsulation technology has shown promise, in its ability to
remarkably improve the drug loading and to encapsulate other platinum drugs such as
carboplatin [175]. The authors envision that further improvements, such as strategies to
mediate endosomal escape, active targeting approaches and optimization of plasma stability,
nanocapsules formulations might translate to the clinic.
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This concept, originally proposed by Ringsdorf [176], is based on covalent attachment of the
drug to a hydrophilic polymer (Fig. 2). Built upon by Duncan, Kopeček and others [11,177],
the approach has proven promising with nearly a dozen polymeric conjugates in clinical
trials. Although most polymer–drug conjugates that have advanced to the clinic rely only on
the EPR effect, numerous preclinical studies suggest opportunities for the tumor-specific
targeting of polymer conjugates using antibodies, peptides and other targeting moieties
[178]. Polymer biocompatibility, presence of proper drug-binding groups and a suitable
linker chemistry allowing drug release and access to the pharmacological target are
important parameters that need to be taken into account upon development of polymer–drug
conjugates. Specifically, polymers containing nitrogen donors such as amines or oxygen
donors such as carboxylates or hydroxyl groups can bind platinum complexes [179]. These
groups can be present either in the polymer main chain, be terminal, or pendant. Depending
upon the platinum complex structure and the drug-binding groups type the complexation of
the drug to the polymer can be monodentate or bidentate.
The N-(2-hydroxypropyl)methacrylamide (HPMA) is the most frequently used polymer for
conjugation of anticancer compounds (Fig. 4). Previously it was used safely as a plasma
expander. The first promising HPMA anticancer drug conjugates used doxorubicin and pac-
litaxel as biological agents [11]. The HPMA-drug conjugates were optimized to ensure that
polymer size is large enough to take advantage of the EPR effect, yet small enough to allow
for the ultimate renal excretion. One of the HPMA–copolymer platinates, AP5280, contains
cisplatin linked through a malonate end group of the polymer [180]. This conjugate with
platinum loading of approximately 10% by weight was at least 20-fold less toxic than
cisplatin in vivo and showed 19-fold increase in platinum accumulation in B16 mouse
tumors. On the basis of the improved therapeutic index evidenced in several other murine
tumor models [181], AP5280 (Access Pharmaceuticals, Inc.) was advanced into clinical
trials. In Phase I/II studies much reduced platinum-related toxicity and promising efficacy
was observed [182,183]. However, further development of the formulation was terminated
as the company opted to focus its development resources on a third-generation polymer-
conjugate AP5346, which is based on improved polymer carrier conjugated to a more potent
DACHPt moiety.
AP5346 or ProLindac (Access Pharmaceuticals, Inc.) is the HPMA–platinum conjugate
currently under clinical development (Table 5, Fig. 4). This 25 kDa polymeric drug
conjugate contains DACHPt bound to hydrophilic HPMA through a pH-sensitive
amidomalonate chelating group [184,185]. The amidomalonate–platinum chelate is stable at
physiological pH but releases the DACHPt at lower pH of extracellular space of hypoxic
tumors or intracellular endosomal–lysosomal compartments [186]. ProLindac has shown
efficacy similar to oxaliplatin in a panel of breast, ovarian, lung and prostate cancer cell
lines [187]. Pre-clinical studies in several mouse tumor models, including both syngeneic
murine and human tumor xenograft models suggested that compared to oxaliplatin
ProLindac displays superior tumor growth inhibition, reduced toxicity towards normal cells,
increased and more sustained plasma platinum levels, and up-to 14-fold increased platinum
delivery to the tumor [184]. Specifically, ProLindac has proven to be better than oxaliplatin
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in three human colon xenograft models (Colo-26, HT-29, and HCT116), as well as in the
L1210 murine leukemia and 0157 hybridoma models [188].
In a Phase I trial ProLindac was well tolerated and shown no neutropenia or significant
hematologic toxicity in patients with advanced solid tumors [189]. Partial responses were
observed in patients with relapsed melanoma, ovarian cancer, and stable disease was
attained in patients with esophageal carcinoma, cisplatin-resistant carcinoma of the cervix,
thyroid cancer, and melanoma [189]. The Phase I study demonstrated that high doses of
ProLindac could be administered safely when patients were adequately pretreated with
antiemetics and hydration [189]. A Phase I/II trial evaluated the anticancer activity of
ProLindac as a single agent for advanced ovarian cancer, previously treated with
organoplatins (except oxaliplatin) [188]. Considering the long half-life of ProLindac
observed in patients, weekly doses were considered unsuitable and dosage was reduced to a
two-hour i.v. infusion every two or three weeks [190]. This treatment was also well tolerated
and resulted in the disease stabilization in a significant number of patients [188,190]. The
side effects experienced by patients were mild at grades 1–2, and without any signs of acute
neurotoxicity [188]. The company, Access Pharmaceuticals, has also tested a new ProLindac
formulation manufactured using a scalable process, intended for future clinical trials. No
adverse events were reported while the formulation retained the beneficial disease
stabilization as seen previously [28]. ProLindac is currently in several Phase II combination
studies with drugs such as paclitaxel and gemcitabine in patients with solid tumor
indications including colorectal and ovarian cancer. In addition, ProLindac has been licensed
to pharmaceutical companies in China and South Korea where further Phase II combination
studies will be conducted in specific tumor types [191].
Polyphosphazenes are biodegradable linear polymers with an inorganic backbone composed
of alternating nitrogen and organically functionalized phosphorus groups and reactive
pendant side groups that may be organic, organometallic or inorganic in nature [192] (Fig.
4). Functionalization with amino acids makes the polymer hydrolytically degradable [193].
Sohn and colleagues have studied a variety of aspartic and glutamic acid derivatized
polyphosphazenes conjugates of platinum drugs. From a series of conjugates incorporating
platinum complexes, DACHPt containing complex glutamate derivatized polyphosphazene
demonstrated high potency both in vitro and in vivo, lacked cross-resistance to cisplatin and
maintained good water solubility [194,195]. A variety of other modified polyphosphazenes–
platinum conjugates were also synthesized and evaluated in vivo [196,197]. The most
promising results however involved amphiphilic polyphosphazene modified with PEG
chains. The conjugate had high cytotoxicity against human cancer cell lines and was found
to selectively accumulate in tumor tissue [198]. Recently, amphiphilic polyphosphazenes–
platinum conjugates with the ability to assemble into stable nanoparticles of size 100–200
nm were also reported [199]. In addition, thermosensitive cyclotriphosphazene–platinum
conjugates with critical solution temperature below body temperature were developed [196].
This conjugate had antitumor activity comparable to the cisplatin in murine leukemia L1210
model although possessed much lower toxicity.
Various other synthetic polymers have also been investigated as carriers for platinum drugs
such as cyclodextrines, polyaminoacids and others. Neuse and colleagues have reported
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several formulations where cisplatin was bound either to the main chain [200,201] or to
pendant groups [202,203] of water-soluble polyamides. Polyaspartamides were found to be
particularly useful for forming platinum complexes yielding a platinum loading ranging
from 4 to 15% [202–204]. Platination was brought about by chelation of carriers containing
ethylenediamine ligands with tetrachloroplatinate, yielding cisplatin-like species. The
structural properties of the various polymers and particularly the nature of the ligand groups
affected the release of platinum hence strongly influencing the anti-proliferative activity of
the complexes [201,205,206]. Lack of cross-resistance with cisplatin was also shown in
cisplatin-resistant A2780-cis cells [207]. Studies in mice demonstrated lower toxicity of
these conjugates with up to 20-times higher maximum tolerated dose in some cases relative
to cisplatin [208]. Platinum-conjugates, bound on polymeric carriers through chelation with
carboxyl or hydroxyl functionalities have also been investigated. Such carriers incorporated
from 5% to 15% of DACHPt as the platinum drug and exhibited a more rapid release profile
compared to amine polymers [209–211]. Selected conjugates had cytotoxicity on par with
cisplatin against the sensitive HeLa and A2780 cancer lines, and up to 10-times higher than
cisplatin against the multidrug-resistant Colo 320 DM and A2780-cis cell lines [209,212].
Favorable pharmacokinetics, reduced toxicity and enhanced selectivity of antitumor activity
were also reported for a set of these conjugates [213].
5.4. Dendrimers in platinum delivery
Dendrimers are of considerable interest for drug delivery and targeting of platinum-drugs to
a large extent due to their highly uniform structure and narrow size distribution, a challenge
with some of the other polymeric technologies [214]. Dendrimers are highly branched
polymers with multiple end groups which allow encapsulation or conjugation of numerous
drug molecules at the surface or in the core [214] (Fig. 2). The dendrimer generation refers
to the number of repeated branching cycles performed during synthesis and defines the
number of branches and terminal groups in the dendrimer structure. With increasing
generation number, dendrimer diameter increases linearly, however the number of
functional groups on the periphery increases exponentially [215]. This in-turn determines
the extent of drug loading and kinetics of drug release. Further modulation in loading and
release can be permitted by incorporation of various degradable linkages between the drug
and dendrimer [216]. There are numerous forms of dendrimers that are made from
polyamidoamines, polyamines, polypeptides, poly(aryl ethers), polyesters, carbohydrates or
DNA [217].
The most frequently reported are polyamidoamines (PAMAM), which are available
commercially with an extensive range of generations and end functional groups [218].
PAMAM dendrimers at the ends of their branches can carry either amino groups (the “full-
generation” dendrimer) or carboxylate groups (the “half-generation” carries [219]. One of
the earliest works on conjugates PAMAM dendrimers with platinum was reported by
Duncan and co-workers [220]. In this cisplatin was linked to the dendrimer G3.5 through the
functionalized sodium carboxylate surface. The conjugate demonstrated increased solubility,
high loading capacity (20–25% by weight), decreased systemic toxicity, selective
accumulation in solid tumors and anticancer activity. Specifically, dendrimer–cisplatin
conjugate induced retardation of growth of the subcutaneous B16F10 murine melanoma,
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while cisplatin alone failed to show any anti-tumor activity [220]. Interestingly, Kirkpatrick
et al. showed that in such conjugates some drug remains bound to the dendrimer even after
prolonged incubation (60 °C, over a week), which is in compliance with formation of
additional bonds. Also drug loading and its release profile depend on the generation of
dendrimers [221]. In another study amino-terminated PAMAM dendrimer was conjugated to
potassium tetrachloroplatinate. However, along with the terminal modification of the
PAMAM branches at the dendrimer surface, a considerable portion of platinum complexes
could link with the secondary and terminal amino groups within the dendrimer core, which
may slow down the drug release [222]. Additionally, the reaction of the PAMAM dendrimer
with the tetrachloroplatinate can induce cross-linking and formation of large aggregates due
to the presence of multiple conjugating groups. Such complication was for example
observed by Bellis et al. who modified poly(propyleneimine) dendrimers [223].
DACHPt conjugation to dendrimers has also been reported. Howell et al. were able to
produce well-defined conjugates of PAMAM dendrimers (G4.5) with carboxylic acid
terminal groups containing up-to 40 DACHPt moieties at the surface [224]. In this study the
bulky DACH ligand groups were expected to reduce the probability of inclusion of the
platinum complexes with interior amines within the dendrimers of this size. These
conjugates retained water solubility and displayed sustained release of active platinum
species over a 24 h period under physiological conditions [225]. Current literature also
presents few other studies on dendrimeric-platinum anticancer drugs [226–228], but no such
study has warranted further development of these conjugates due to their relatively modest
efficiency.
5.5. Platinum complexes in nanotubes
Nanotubes are tubular structures with at least one dimension, a diameter, in the nanometer
scale [229] (Fig. 2). Examples include Single-Walled Carbon Nanotubes (SWCNTs) or
Multi-Walled Carbon Nanotubes (MWCNTs) as well as cyclic peptide nanotubes and
template-synthesized nanotubes. Nanotubes offer some interesting advantages relative to
spherical nanoparticles for drug delivery applications. The presence of the open ends and
large inner volume (relative to the volume of the tube) permit incorporation of
pharmaceutical species at high loading capacities with ease. Additionally, the inner and
outer surfaces of the nanotubes can be differentially modified with chemical or biochemical
functionalities and this can be exploited for conjugating targeting ligands or grafting PEG to
increase biocompatibility of the nanotubes [230]. The toxicity of SWCNTs appears to be
low despite long term accumulation in vivo [231].
Ajima et al. demonstrated possibility to incorporate and release cisplatin in SWCNTs. The
released cisplatin retained ability to kill human lung cancer cells while the SWCNTs
themselves were not cytotoxic [232]. Molecular modeling studies have shown that to host
cisplatin the radius of carbon nanotubes must be at least 4.8 Å while the maximum uptake of
cisplatin is observed when nanotube radius is approximately 5.3 Å [233]. Although this
model represents only a first approximation, it provides overall guidelines towards selection
of appropriately sized nanotubes [234]. Cisplatin loading and release was also altered by
chemical modification of the structural holes in the SWCNTs and the overall amounts of
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incorporated and released cisplatin were increased by modification compared to unmodified
nanotubes [235]. Moreover, the in vitro anticancer activity of cisplatin loaded in modified
nanotubes was also increased and such drug, loaded nanotubes displayed a marked tumor
suppression in vivo [236]. Interestingly the unloaded nanotubes also exhibited some anti-
tumor effect.
Lippard and colleagues produced conjugates of amine-functionalized water-soluble
SWCNTs with a platinum prodrug derivatized from cisplatin [237]. The Pt(IV) complex,
c,c,t-[Pt(NH3)2Cl2(OEt)(O2CCH2CH2CO2H)], was tethered to the surface of the carbon
nanotubes through peptide linkages. The SWNTs were taken into testicular cancer cells by
endocytosis, where the drop in pH facilitated reductive release of the Pt(II) core complex.
The cytotoxicity of the free platinum(IV) complex was shown to increase by >100-fold upon
conjugation with the nanotubes [237]. Further studies were carried out using a folate
modiied nanotubes, which demonstrated selective accumulation and enhanced antitumor
activity towards folate receptor-positive cancer cells [238]. Targeted nanotube–platinum
conjugates have also been reported by Bhirde et al., who used epidermal growth factor
(EGF) attached to SWNTs to specifically target EGF overexpressing head and neck
squamous carcinoma cells [239]. The targeted nanotubes also showed selective
accumulation in mice xenografts leading to significant regression of tumor growth compared
to controls [240].
5.6. Platinum delivery using polymer micelles
Polymer micelles (Fig. 5) are aggregates of block copolymers with the core-shell
architecture [241]. They can entrap drugs, generally in the micelle core and increase the
apparent solubility of a drug, thus greatly exceeding its intrinsic solubility in water. The ease
of micelle preparation and drug loading, along with the ability to alter chemical
composition, total molecular mass, and block lengths of the block copolymers, permits to
precisely control the size and morphology of the micelles, which is of importance for their
pharmaceutical use [242]. Polymer micelle-based compositions of various drugs have been
investigated for parenteral, oral [243–245], nasal [246,247], and ocular [248,249] delivery
routes. Many of these studies demonstrated clear benefits including increased bioavailability
or reduced adverse effects of the drugs. The block copolymer micelles can be sub-
categorized in at least two main groups, depending upon the type of intermolecular forces
driving the segregation of the core-forming block in the aqueous environment. The first
group is amphiphilic block copolymer micelles having the core formed by hydrophobic
interactions amongst the water-insoluble blocks of the block copolymer and the shell formed
by the water soluble blocks [10]. They self-assemble due to aggregation of amphiphilic
block copolymers having hydrophobic and hydrophilic blocks in water at concentrations
above critical micelle concentration (CMC). The second group is block ionomer complexes
(BICs) or polyion complex (PICs) micelles, which have the core formed by electrostatic
interactions of the polyion block of the block copolymer with oppositely charged species—
natural and synthetic polyelectrolytes (including ionic blocks of other block copolymers),
surfactants, and metal ions [250–252]. One specific type of BICs, the block copolymer–
metal complex micelles is spontaneously formed in aqueous media as a result of electrostatic
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neutralization [253] and/or coordination of transition metal ions with the polyion blocks
[254,255].
Amphiphilic block copolymer micelles are well-suited for solubilization of hydrophobic
drugs [10,256,257]. Some of such micelles display unprecedented high loading capacity of
nearly 50 wt.% with respect to very poorly soluble single drugs as well as drug
combinations [258,259]. Generally, the spatial distribution of the solubilized drug within the
micelle depends upon the drug polarity. Hydrophobic drugs distribute into the micelle core
while drugs with intermediate and higher polarity occupy more peripheral positions [10].
The drug distribution correlates well with the strength of association between the micelle
and the drug and in turn determines the release profile of the drug with more peripherally
located drug more amenable to release [10]. Hydrophilic drugs can be adsorbed in the
micelle corona, however this interaction is usually weak. The same holds true for cisplatin
and some other platinum drugs, which are too soluble in aqueous media to be encapsulated
in the hydrophobic micelle core. This limitation has been overcome using block ionomers,
which can form polymer–metal complexes. Incorporation of platinum drugs into such
complexes proceeds though formation of coordination bonds between these platinates and
the polyion block of the block copolymer, which also induces the micelle formation [179].
Copolymers containing polycarboxylates as the ionic blocks has been the choice for this
purpose due to the ability of carboxylic groups to substitute anionic ligands X2 in the
platinum complexes, such as chloride ligands in cisplatin. Most platinum complexes have
two leaving groups and can form complexes with the copolymer through a bidentate
binding. Thus loading of BICs with platinum drugs can also result in the cross-linking of the
micelle core involving two carboxylic groups located in two separate block ionomer chains
[254]. The low nucleophilicity of carboxylic groups permits release of the active platinates
at the physiological concentrations of salts. The release of platinum complexes depends on
the external salt conditions, pH and overall BIC micelle stability [260,261]. In in vivo
conditions, it is likely that the micelle disruption precedes any significant drug release from
the carrier. This may be due to strong dilution of the BIC micelles in the blood that favors
the formation of the platinum-bound copolymer unimers. Biologically abundant counterions
having access to the platinum–polymer complex may subsequently promote the drug release
by ligand exchange [179].
Poly(amino acid) based copolymers, such as poly(aspartic acid), PAsp and poly(glutamic
acid), PGlu, have been the most widely used for platinum drug delivery [262]. Kataoka and
colleagues were the first to describe complexation of cisplatin with PEG–PAsp
[254,263,264] copolymers, which led to the spontaneous formation of stable polymer
micelles with high drug loading. Initial studies demonstrated 1) formation of such polymer
micelles with the sizes ranging from 20 to 100 nm and narrow size distribution, 2) sustained
release of platinum complexes from the micelles via exchange with chloride ions and 3) the
dependence of the drug release on the PAsp block length [254]. Under the physiological salt
concentrations the micelles were stable for about 10 h, which was followed by their gradual
dissociation. Blending of the PEG–PAsp block ionomers with the PAsp homopolymer was
shown to alter the micelle size, the micelle decay and the cisplatin release [263]. Studies in
mice demonstrated that incorporation of cisplatin in such polymer micelles prevented the
Oberoi et al. Page 20






















kidney toxicity of the drug, increased circulation of the micelle bound drug in plasma and
increased exposure of the drug to the tumors [264].
Further studies were carried out with PGlu-based micelles which have improved stability
and drug release characteristics compared to PAsp-based micelles [265]. The sizes of these
micelles are about 30nm. In preclinical studies they exhibited prolonged blood circulation
and accumulation in solid tumors. Significant antitumor activity was observed in C26 tumor-
bearing mice model with some animals showing complete tumor regression without any
significant body weight loss typical of the free drug treatment [265]. Notably,
histopathological and biochemical studies have not revealed any significant nephrotoxicity
of the micelle bound drug, although some transient hepatotoxicity was observed post-
treatment [266]. Moreover, these cisplatin-incorporating micelles were found to decrease
ototoxicity in a guinea pig model, indicating a safer toxicity profile than cisplatin [267]. This
formulation is at the final clinical stage, i.e. Phase III, in Asia under the development name
NC-6004 (Nanoplatin; NanoCarrier Co., Ltd.; Japan). Phase I clinical studies demonstrated
that NC-6004 has significantly better tolerability than free cisplatin, without inducing
significant nephrotoxicity, while other side effects were generally mild [268]. A Phase II
study of NC-6004, combined with gemcitabine, in patients with locally advanced or
metastatic pancreatic cancer showed that Pt hypersensitivity could be completely inhibited
by using prophylactic treatment, and there was no need for pre-hydration, opposing
conventional cisplatin treatment. Moreover, in this study, 2 patients treated with NC-6004
showed partial response (11.8%; total number of patients: 17), while stable disease was
found in 9 patients (52.9%), resulting in a disease control ratio of 64.7%. Importantly,
median overall survival was 12.3 months, which is better than the 7.5 months overall median
survival reported for cisplatin/gemcitabine combination [269]. These results suggest that
NC-6004/gemcitabin combination could be a substitute for the cisplatin/gemcitabin
combination therapy. As for Japan and the USA, a Phase I study of these micelles started in
2012 for various solid tumors and an application for investigational new drug (IND) was
submitted to FDA in 2013, respectively.
A second generation of platinate micelles has been recently prepared by using the parent
complex of oxaliplatin, i.e. DACHPt [270,271]. The diameter of these micelles was 30 nm,
which was comparable to cisplatin-incorporating micelles. The relatively small size of these
micelles allowed deep penetration to tumor tissues, even in poorly permeable tumors, such
as intractable pancreatic cancer [272] and scirrhous gastric cancer [273], leading to
enhanced antitumor efficacy. Moreover, the DACHPt-incorporating micelles were able to
overcome acquired resistance to oxaliplatin in vivo due to their selective drug release at the
perinuclear region, which increased the delivery of the Pt drug to DNA while circumventing
resistance mechanisms in the cytoplasm [274]. The ability of these micelles for prolonged
chemotherapy cycles was confirmed in a recent paper, by using a transgenic model of
spontaneous pancreatic cancer. Accordingly, by injecting the micelles once a week, the mice
survival was extended for more than 100 days, preventing the development of
intraperitoneal metastasis, while for oxaliplatin, approximately 50% of the animals were
dead after 50 days [275]. This micelle formulation is being developed under the name
NC-4016 (NanoCarrier Co., Ltd.; Japan), and will be starting a Phase I/II clinical evaluation
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at The University of Texas MD Anderson Cancer Center (Houston, TX), against various
solid tumors.
Polymer micelles based on biodegradable polyester block copolymer PEG-b-
polycaprolactone (PEG-b-PCL) were also used for incorporation of cisplatin with high
encapsulation efficiency. Anti-tumor activity of such micelles was demonstrated in vitro and
in vivo [276]. Another study by Xu et al. described pH responsive polymer micelles with
poly2-(N,N-dimethylamino)ethyl methacrylate cores for cisplatin delivery capable of rapid
endosomal release of the drug [277]. Such micelles were more active against ovarian tumors
compared to non-pH sensitive PEG-b-PCL based micelles and cisplatin alone. Graft
copolymers were also investigated for cisplatin delivery. Thus, biodegradable poly(beta-
aminoester)-g-PEG reacted with cis-platin and formed 100–200 nm particles, which
displayed similar anticancer activity against SKOV-3 tumor xenografts in mice as cisplatin
alone [278]. PEG-g-poly((N-amino acidyl)-DL-aspartamide) formed with cisplatin 80–160
nm spherical particles [279]. Such cisplatin-loaded polymer micelles were also modified
with folate groups and evaluated against folate receptor positive KB cell-derived tumors.
The antitumor efficacy of the folate-modified polymer micelles was less than that of the free
cisplatin [280]. However, the mi-cellar form of cisplatin demonstrated significantly lower
toxicity than the free drug [280]. PEG-derivatized hyperbranched polyglycerols (HPGs) with
hydrophobic cores further functionalized with carboxylate groups were shown to bind up to
10–20% cisplatin (w/w) and form small 5–10 nm micelles [281]. Carboxylated HPGs
demonstrated good biocompatibility, and effectively inhibited proliferation of KU-7-luc
bladder cancer cells.
Another type of polymer micelles for delivery of cisplatin was prepared by the metal ion
condensation, self-assembly and cross-linking of ionic blocks of doubly hydrophilic block
copolymers, such as PEG-b-(polymethacrylic acid) (PEG-b-PMAA). Following removal of
the condensing metal ions the soft nanospheres were formed of about 100 nm in diameter,
which contained cross-linked PMAA ionic cores surrounded by hydrophilic PEG shells. In
aqueous environment such micelles behave as nanoscale ionic gels (nanogels), capable of
swelling and changing charge in response to environmental changes (pH or ionic strength)
[282].
An important variable in such polymer micelles was the extent of cross-linking which
revealed an optimum for efficient drug delivery systems. While at low cross-linking extents
the micelle structure was not adequately reinforced, the excessive cross-linking reduced the
free volume of the core and led to a decrease in the drug loading capacity [261]. The cross-
linked micelles with an optimal cross-linking density exhibited a cisplatin loading capacity
of ~30% w/w, were stable against dilution in the body fluids and displayed ability for
sustained release of the drug species [261]. They were rapidly internalized in human A2780
ovarian carcinoma cells in culture. Prolonged blood circulation, increased tumor
accumulation, enhanced antitumor effect, and reduced toxicity relative to the free drug were
also shown for this system [283]. Although a strong accumulation of drug-loaded micelles
was also seen in the liver and the spleen, a detailed toxicity analysis did not reveal any
untoward toxicity. Targeted delivery of platinum drugs was examined using such cross-
linked polymer micelles decorated with the folate groups [284]. Folate-conjugated micelles
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were shown to carry their drug cargo selectively to targeted cell populations expressing
folate receptors. Furthermore, they also demonstrated superior antitumor efficacy in a
xenograft tumor model and a decrease in renal toxicity associated with cisplatin. Recently
similar approach was applied to encapsulate DACHPt. This formulation had properties
similar to cisplatin-loaded micelles such as high drug loading (~25% w/w), controlled pH
dependent release of platinum species, and an improved antitumor activity compared to the
free drug (oxaliplatin) [285].
Studies on micelle delivery of platinum complexes other than cisplatin are scarce. Duong et
al. reported incorporation of cisplatin derived Pt(IV) into 36 nm micelles while
simultaneously cross-linking the micelle core [286]. The approach allowed reduction of
Pt(IV) under reductive environment, such as inside the cell, leading to the disintegration of
the core-cross-linked micelles. Jadhav et al. reported encapsulation of a hydrophobic and
water-insoluble Pt(II) compound, cis-(cha)2Pt(NO3)2 into amphiphilic cyclotriphosphazene-
based micelles [287]. The micelle-encapsulated Pt(II) compound exhibited improved
cellular uptake in vitro, along with improved pharmacokinetics profile and specific tumor
accumulation in rats.
6. Conclusions
Platinum anticancer complexes have made a profound impact on cancer management, but
their clinical use has its share of limitations. Almost half a century worth of research effort
focused on finding superior platinum complexes, seems to have hit a roadblock.
Nanocarrier-based delivery of platinum complexes is a viable alternative that has emerged
during the last decade. Liposomal constructs at present numerically lead the domain of
platinum-carriers under clinical evaluation, but other new polymeric technologies are
becoming increasingly visible. While the focus so far has been on the EPR guided delivery
of these constructs to tumor targets, active targeting using specific biomolecular interactions
may hold the key to a future therapeutic approach. Recent years have also seen a shift in
emphasis from first generation cisplatin analogues as the drug payload to the more effective
third generation DACHPt analogues. Most studies described here, demonstrated the ability
of carriers to deliver higher platinum dosage at the tumor site, reduce non-target toxicity,
and in some cases evade platinum drug resistance, significant milestones as such. However,
the potent antitumor response seen in preclinical studies has rarely been translated to
humans, a limitation of the current technology, which might impede its rapid penetration to
clinic. Regulatory agencies have denied approval to several platinum complexes, which
demonstrated better safety profile, but lacked superior antitumor activity compared to free
drugs. Clearly the strength of interaction between the platinum drug and the carrier is central
to their performance. Therefore, future design of these carriers will have to insure efficient
drug release in the tumor environment since only the free platinum complexes are
therapeutically effective. Efforts need to be focused on engineering the drug delivery
systems with tumor responsive cues to trigger drug release inside the tumors and tumor
cells, and codelivery of platinum resistance modulators. Having said that, there are plenty of
opportunities for further improvement in this field and the future of some of these
technologies appears promising.
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Schematic illustration of cellular accumulation of cisplatin, its intracellular aquation,
activation of cellular signaling pathways by platinum induced DNA damage and the
resultant cell death.
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Various therapeutic macromolecular carriers for platinum drug delivery currently under
preclinical and clinical development.
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Schematic illustration of conventional, ‘stealth’ and targeted liposomal platforms for
platinum drug delivery. Liposomes can be made ‘stealth’ by incorporation of PEG-
conjugated phospholipids or by incorporation of PEG containing polymers such as
Pluronics. Further conjugation of a targeting ligand can be achieved by using a
functionalized PEG chain.
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Chemical structures of polymer–platinum conjugates.
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Schematic illustration of polymer micelle platforms for platinum drug delivery.
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Table 2
Platinum complexes in clinical evaluation.
Complex Synonyms Structure Regulatory status Clinical use
Picoplatin JM473 Phase II Metastatic colorectal cancer
NX473 Phase II Metastatic castration-
resistant prostate cancer
ZD0473
AMD0473 Phase II Refractory or resistant
ovarian cancer
Amminedichloro (2-methylpyridine)platinum(II) Phase III Refractory or progressed
SCLC
BBR3464 Triplatin tetranitrate Phase II Gastric and oesophageal
adenocarcinoma
Satraplatin JM216 Phase II Metastatic castrate-
refractory prostate cancer
BMY 45594
BMS 182751 (OC-6-43)-bis(acetato) Phase II Metastatic androgen-
independent prostate cancer
amminedichlorocyclohexylamine platinum(IV)
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Table 3
Proteins that specifically recognize cisplatin-damaged DNA (modified from Jung and Lippard [58]).
Protein Function
a XPA b NER: damage recognition protein
a XPC b NER: damage recognition protein
RPA b NER: damage recognition protein
hMSH2 c MMR: damage recognition protein
hMUTSα c MMR: damage recognition protein
Ku80 d DNA-PK: DNA-binding subunit
HMGB1 Non-histone chromatin protein and extracellular signaling protein
SSRP1 Chromatin modulator
hUBF rRNA transcription factor
tsHMG Testis-specific HMG protein
TBP Transcription initiation factor
p53 Tumor suppressor protein
PARP-1 Poly(ADP-ribose) polymerase
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Table 4
Platinum complexes which entered clinical trials but were not given marketing approval (compiled from
Lebwohl and Canetta [21], Jakupec et al. [19] and Wheate et al. [28]).
Entered clinical trials in Compound Abandonment stage Limiting toxicity
1970s PAD (NSC 170898) Phase I Insufficient solubility
Platinum uracil blue (PUB) Phase I Cardiac toxicity
MBA Phase I Severe hypersensitivity
JM-20 (SHP) Phase I Severe allergic reactions
JM-74 (PHM) Phase II Nephrotoxicity, inferior activity
Neo-SHP Phase I Severe allergic reactions
Neo-PHM Phase II Nephrotoxicity, inferior activity
BOP Phase I Insufficient solubility
1980s Iproplatin (JM-9) Phase III Low activity
JM-82 (DACCP) Phase II Chemical instability, low activity
JM-11 Phase I Poor pharmacokinetics
Spiroplatin (TNO-6) Phase II Nephrotoxicity
PYP Phase I Nephrotoxicity and myelosuppression
JM-40 Phase I Nephrotoxicity
PHIC Phase I Difficulties in synthesis
CI-973 (NK-121) Phase II Lack of activity
DWA2114R (Miboplatin) Phase III No advantage over cisplatin
Enloplatin Phase II Nephrotoxicity
Zeniplatin Phase II Nephrotoxicity
1990s Ormaplatin (Tetraplatin) Phase I Neurotoxicity
Cycloplatam Phase II Hematological toxicity
JM-216 (Satraplatin) Phase III Low activity
ZD0473 (AMD473) Phase I Unknown
TRK-710 Phase I Unknown
BBR3464 (Triplatin) Phase II Poor response rates
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